Adherence to growth hormone therapy: Results of a multicenter study

Endocrine Practice

Volumn 20, Issue 1, 2014, Pages 46-51

  Aydin, Banu Küçükemre ^a   Aycan, Zehra ^b,c   Şiklar, Zeynep ^d   Berberoǧlu, Merih ^d   Öcal, Gönül ^d   Çetinkaya, Semra ^b   Baş, Veysel ^b   Kendirci, Havva ^b   Çetinkaya, Ergun ^c,e   Darcan, Şükran ^f   Gökşen, Damla ^f   Evliyaoǧlu, Olcay ^g,h   Şükür, Mine ^a   Baş, Firdevs ^a   Darendeliler, Feyza ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Children's Health and Disease Training and Research Hospital   (United States)

^c Ankara Children's Diseases and Hematology Oncology Training Hospital   (Turkey)

^d Faculty of Medicine   (Turkey)

^e Endomer Pediatric Endocrinology Center   (Turkey)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; CHILD; ENDOCRINOLOGY; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HORMONAL THERAPY; HUMAN; INFANT; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; SCHOOL CHILD; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME; TURNER SYNDROME; CLINICAL TRIAL; DEFICIENCY; DRUG EFFECTS; GROWTH; MEDICATION COMPLIANCE; MULTICENTER STUDY;

ADOLESCENT; CHILD; FEMALE; GROWTH; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MEDICATION ADHERENCE;

EID: 84892750289     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13194.OR     Document Type: Article

References (25)

1. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-550.
2. Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS ONE. 2011; 6:e16223.
3. Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther. 2008;30:307-316.
4. Cromer BA, Tarnowski KJ. Noncompliance in adolescents: a review. J Dev Behav Pediatr. 1989;10:207-215.
5. Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93:147-148.
6. Haverkamp F, Gasteyger C. A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ. 2011;14:448-457.
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
8. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
9. Rittenhouse BE. A novel compliance assessment technique. The Randomized Response Interview. Int J Technol Assess Health Care. 1996;12:498-510.
10. Oyarzabal M, Aliaga M, Chueca M, Echarte G, Ulied A. Multicentre survey on compliance with growth hormone therapy: what can be improved? Acta Paediatr. 1998;87: 387-391.
11. Norgren S. Adherence remains a challenge for patients receiving growth hormone therapy. Pediatr Endocrinol Rev. 2009;6(suppl 4):545-548.
12. Gökçay G, Furman A, Neyzi O. Updated growth curves for Turkish children aged 15 days to 60 months. Child Care Health Dev. 2008;34:454-463.
13. Neyzi O, Furman A, Bundak R, Gunoz H, Darendeliler F, Bas F. Growth references for Turkish children aged 6 to 18 years. Acta Paediatr. 2006;95:1635-1641.
14. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child. 1966;41:454-471.
15. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child. 1966;41:613-635.
16. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child.1969;44:291-303.
17. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13-23.
18. Smith SL, Hindmarsh PC, Brook CG. Compliance with growth hormone treatment - are they getting it? Arch Dis Child. 1993;68:91-93.
19. Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79:189-196.
20. Siklar Z, Öcal G, Berberoǧlu M, Bilir P. Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients. J Clin Res Pediatr Endocrinol. 2009;1:240-243.
21. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000;85:3990-3993.
22. Higham CE, Jostel A, Trainer PJ. IGF-I measurements in the monitoring of GH therapy. Pituitary. 2007;10:159-163.
23. Pawlikowska-Haddal A, Cohen P, Cook DM. How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? Pituitary. 2012;15:126-134.
24. Gács G, Hosszu E. The effect of socio-economic conditions on the time of diagnosis and compliance during treatment in growth hormone deficiency. Acta Paediatr Hung. 1991;31:215-221.
25. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14:143-154.